ertugliflozin
Selected indexed studies
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. (N Engl J Med, 2020) [PMID:32966714]
- Ertugliflozin: First Global Approval. (Drugs, 2018) [PMID:29476348]
- Ertugliflozin for the treatment of type 2 diabetes. (Drugs Today (Barc), 2019) [PMID:30938372]
_Worker-drafted node — pending editorial review._
Connections
ertugliflozin is a side effect of
Sources
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. (2020) pubmed
- Ertugliflozin: First Global Approval. (2018) pubmed
- Ertugliflozin for the treatment of type 2 diabetes. (2019) pubmed
- Ertugliflozin in the treatment of type 2 diabetes mellitus. (2020) pubmed
- Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial. (2024) pubmed
- Ertugliflozin. (2006) pubmed
- Role of Ertugliflozin in the Management of Diabetes Mellitus. (2022) pubmed
- Ertugliflozin as a monotherapy for the treatment of type 2 diabetes. (2018) pubmed
- Ertugliflozin for type 2 diabetes. (2019) pubmed
- Ertugliflozin for treatment of patients with Type 2 diabetes mellitus. (2018) pubmed